IMP3 signatures of fallopian tube: a risk for pelvic serous cancers

Persistent Link:
http://hdl.handle.net/10150/610186
Title:
IMP3 signatures of fallopian tube: a risk for pelvic serous cancers
Author:
Wang, Yiying; Wang, Yue; Li, Dake; Li, Lingmin; Zhang, Wenjing; Yao, Guang; Jiang, Zhong; Zheng, Wenxin
Affiliation:
Department of Obstetrics and Gynecology, Henan Provincial People’s Hospital, Zhengzhou, China; Department of Pathology, University of Arizona College of Medicine, Tucson, AZ, USA; Department of Obstetrics and Gynecology, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu, China; Department of Pathology, Shanxi Medical University, Shanxi, China; Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China; Arizona Cancer Center, University of Arizona, Tucson, AZ, USA; Department of Molecular & Cellular Biology, University of Arizona, Tucson, AZ, USA; Department of Obstetrics and Gynecology, University of Arizona, Tucson, AZ, USA; Department of Pathology, University of Massachusetts Medical Center, Worcester, MA, USA
Issue Date:
2014
Publisher:
BioMed Central
Citation:
Wang et al. Journal of Hematology & Oncology 2014, 7:49 http://www.jhoonline.org/content/1/1/49
Journal:
Journal of Hematology & Oncology
Rights:
© 2014 Wang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
Collection Information:
This item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.
Abstract:
BACKGROUND:Recent advances suggest fallopian tube as the main cellular source for women's pelvic serous carcinoma (PSC). In addition to TP53 mutations, many other genetic changes are involved in pelvic serous carcinogenesis. IMP3 is an oncofetal protein which has recently been observed to be overexpressed in benign-looking tubal epithelia. Such findings prompted us to examine the relationship between IMP3 over-expression, patient age and the likelihood of development of PSC.METHODS:Fallopian tubes from three groups (low-risk, high-risk, and PSC) of patients with matched ages were studied. Age was recorded in 10years intervals ranging from age 20 to older than 80. The number of IMP3 signatures (defined by 10 or more tubal secretory cells stained positively and continuously in benign appearing tubal mucosa) from both tubal fimbria and ampulla segments was measured. The data was analyzed by standard contingency table and Poisson distribution methods after age adjustment. IMP3 overexpression was also examined in serous tubal intraepithelial carcinoma and PSC.RESULTS:The positive IMP3-stained cells are mainly tubal secretory cells. The absolute number of tubal IMP3 signatures increased significantly within each age group. Age remained a significant risk factor for serous neoplasia after age adjustment. IMP3 signatures were more frequent in the patients of both high-risk and PSC groups. The presence of IMP3 signatures in tubal mucosa was significantly associated with tubal or pelvic serous carcinogenesis (p<0.001).CONCLUSIONS:The findings suggest that tubal secretory cells with IMP3 signatures showing growth advantage could potentially serve as a latent precancer biomarker for tubal or pelvic serous carcinomas in women.
EISSN:
1756-8722
DOI:
10.1186/s13045-014-0049-5
Keywords:
IMP3 signature; Fallopian tube; Tubal secretory cells; Ovarian cancer; Pelvic serous carcinoma
Version:
Final published version
Additional Links:
http://www.jhoonline.org/content/7/1/49

Full metadata record

DC FieldValue Language
dc.contributor.authorWang, Yiyingen
dc.contributor.authorWang, Yueen
dc.contributor.authorLi, Dakeen
dc.contributor.authorLi, Lingminen
dc.contributor.authorZhang, Wenjingen
dc.contributor.authorYao, Guangen
dc.contributor.authorJiang, Zhongen
dc.contributor.authorZheng, Wenxinen
dc.date.accessioned2016-05-20T09:00:34Z-
dc.date.available2016-05-20T09:00:34Z-
dc.date.issued2014en
dc.identifier.citationWang et al. Journal of Hematology & Oncology 2014, 7:49 http://www.jhoonline.org/content/1/1/49en
dc.identifier.doi10.1186/s13045-014-0049-5en
dc.identifier.urihttp://hdl.handle.net/10150/610186-
dc.description.abstractBACKGROUND:Recent advances suggest fallopian tube as the main cellular source for women's pelvic serous carcinoma (PSC). In addition to TP53 mutations, many other genetic changes are involved in pelvic serous carcinogenesis. IMP3 is an oncofetal protein which has recently been observed to be overexpressed in benign-looking tubal epithelia. Such findings prompted us to examine the relationship between IMP3 over-expression, patient age and the likelihood of development of PSC.METHODS:Fallopian tubes from three groups (low-risk, high-risk, and PSC) of patients with matched ages were studied. Age was recorded in 10years intervals ranging from age 20 to older than 80. The number of IMP3 signatures (defined by 10 or more tubal secretory cells stained positively and continuously in benign appearing tubal mucosa) from both tubal fimbria and ampulla segments was measured. The data was analyzed by standard contingency table and Poisson distribution methods after age adjustment. IMP3 overexpression was also examined in serous tubal intraepithelial carcinoma and PSC.RESULTS:The positive IMP3-stained cells are mainly tubal secretory cells. The absolute number of tubal IMP3 signatures increased significantly within each age group. Age remained a significant risk factor for serous neoplasia after age adjustment. IMP3 signatures were more frequent in the patients of both high-risk and PSC groups. The presence of IMP3 signatures in tubal mucosa was significantly associated with tubal or pelvic serous carcinogenesis (p<0.001).CONCLUSIONS:The findings suggest that tubal secretory cells with IMP3 signatures showing growth advantage could potentially serve as a latent precancer biomarker for tubal or pelvic serous carcinomas in women.en
dc.language.isoenen
dc.publisherBioMed Centralen
dc.relation.urlhttp://www.jhoonline.org/content/7/1/49en
dc.rights© 2014 Wang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)en
dc.subjectIMP3 signatureen
dc.subjectFallopian tubeen
dc.subjectTubal secretory cellsen
dc.subjectOvarian canceren
dc.subjectPelvic serous carcinomaen
dc.titleIMP3 signatures of fallopian tube: a risk for pelvic serous cancersen
dc.typeArticleen
dc.identifier.eissn1756-8722en
dc.contributor.departmentDepartment of Obstetrics and Gynecology, Henan Provincial People’s Hospital, Zhengzhou, Chinaen
dc.contributor.departmentDepartment of Pathology, University of Arizona College of Medicine, Tucson, AZ, USAen
dc.contributor.departmentDepartment of Obstetrics and Gynecology, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu, Chinaen
dc.contributor.departmentDepartment of Pathology, Shanxi Medical University, Shanxi, Chinaen
dc.contributor.departmentDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, Chinaen
dc.contributor.departmentArizona Cancer Center, University of Arizona, Tucson, AZ, USAen
dc.contributor.departmentDepartment of Molecular & Cellular Biology, University of Arizona, Tucson, AZ, USAen
dc.contributor.departmentDepartment of Obstetrics and Gynecology, University of Arizona, Tucson, AZ, USAen
dc.contributor.departmentDepartment of Pathology, University of Massachusetts Medical Center, Worcester, MA, USAen
dc.identifier.journalJournal of Hematology & Oncologyen
dc.description.collectioninformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.